Results 201 to 210 of about 1,320,527 (284)

Disulfiram Attenuates Adenine‐Induced Renal Fibrosis by Modulating Inflammatory and Immunometabolic Responses

The FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Chronic kidney disease (CKD) is characterized by persistent inflammation that drives progressive renal injury and fibrosis. In this study, we demonstrate that disulfiram markedly attenuates kidney injury and fibrosis in adenine‐induced nephropathy by suppressing innate immune responses and reducing DNA damage and cellular senescence.
Saori Kin, Yuji Oe, Shun Ishigaki, Ichiro Fujio, Mariko Miyazaki, Tetsuhiro Tanaka   +5 more
wiley   +1 more source

Review of Hyperkalemia Profile for Mineralocorticoid Receptor Antagonist in Patients with Chronic Kidney Disease and Type 2 Diabetes.

Cardiorenal Med
Kendrick JB, Dixon AM.
europepmc   +1 more source

A Novel SXXLF Motif in the FXR N‐Terminal Domain Mediates Coregulator and Interdomain Interactions

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
Farnesoid X receptor (FXR)‐N‐terminal domain (NTD) regulates transcriptional activity through interdomain communication with the LBD and is also involved in co‐activator recruitment. The SENLF motif is the first defined functional element within the FXR‐NTD and mediates both NTD–LBD interaction and selective co‐activator engagements to drive NTD ...
Priscilla Villalona, Thilini Pulahinge, Tracy Yu, Jordan Wenning, Sabab Hasan Khan, Crawford Joseph Frisbie, Jill Magafas, Addison Barbe, C. Denise Okafor   +8 more
wiley   +1 more source

Primary Hyperaldosteronism as a Cause of Resistant Hypertension: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT In young patients with resistant hypertension and hypokalemia, primary hyperaldosteronism should be suspected. Biochemical assessment and adrenal imaging could identify surgically curable aldosterone‐producing adenomas, and a normalization of blood pressure, potassium levels, and symptom resolution can be achieved through adrenalectomy.
Wasif Majeed Chaudhry, Shazia N. Ibnerasa, Waleed Ahmad, Mohammed Hammad Jaber Amin   +3 more
wiley   +1 more source

Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease. [PDF]

Egypt Heart J
Pradhan A, Tripathi UC.
europepmc   +1 more source

Comparison of Guideline‐Directed Medical Therapy in Black versus White Patients With Heart Failure With Reduced Ejection Fraction in a Large, Integrated Health Care System

Clinical Cardiology, Volume 49, Issue 9, September 2026.
Using real‐world data, this study identified differences in recommended GDMT treatment between Black and White HFrEF patients. Black patients were more likely to be treated with MRAs than White patients. Among those treated with GDMT, Black patients were more likely to be treated to target with ACEi/ARB/ARNis and MRAs.
Natalia C. Berry, Yi‐Shin Sheu, Karen Chesbrough, R. Clayton Bishop, Suma Vupputuri   +4 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonist Use Among Patients With Chronic Kidney Disease Who Transitioned to Dialysis. [PDF]

Kidney Med
Tong EM, Zhou H, Pak K, Huang CW, Broder BI, Sim JJ.   +5 more
europepmc   +1 more source

Prospective Evaluation of Quality‐of‐Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION‐HF 12‐Month Results

Clinical Cardiology, Volume 49, Issue 9, September 2026.
Among patients with HFrEF, initiation of dapagliflozin resulted in significant improvements in quality of life, as demonstrated by increased KCCQ‐23 scores during follow‐up. ABSTRACT Introduction Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge ...
Victoria Potoupni, Aristi Boulmpou, Spyridon Maragkoudakis, Alexandros Briasoulis, Emmanouil Foukarakis, Alexia Stavrati, Konstantinos Papadopoulos, Katerina K. Naka, Anna Kotsia, Ioannis Parissis, Antonios Ziakas, Stamatis Adamopoulos, Dimitrios Tziakas, Sotirios Patsilinakos, Melanie Konstantinidou, Periklis Davlouros, Zacharias Christogiannis, Konstantinos Tsitlakidis, Ioannis Pantelakis, Georgios Stefanakis, Marios Kolios, Ioannis Baltogiannis, Evangelos Voltyrakis, Christos Varounis, Andreas Samothrakitis, Dimitrios Krikidis, Panagiotis Tsialoukis, Zoe Paparepa, Dimitrios Gourlis, Nikolaos Papoutsidakis, Apostolos Karavidas, Christodoulos Papadopoulos   +31 more
wiley   +1 more source

Long‐Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3–4 Chronic Kidney Disease: A 24‐Month Single‐Centre Cohort

Clinical Cardiology, Volume 49, Issue 9, September 2026.
In this 24‐month, single‐centre cohort of 360 patients with HFrEF and stage 3–4 chronic kidney disease, sacubitril/valsartan was well tolerated, with stable renal function, improved symptoms, and low rates of renal events and mortality. These descriptive findings are hypothesis‐generating and warrant confirmation in controlled studies.
Fatih Akkaya, Onur Osman Şeker, Ercan Türkmen, Seçkin Dereli   +3 more
wiley   +1 more source

Management Strategies for Potassium Levels During Non-steroidal Mineralocorticoid Receptor Antagonist Therapy: A Comprehensive Review. [PDF]

Electrolyte Blood Press
Son HE.
europepmc   +1 more source